Testing frexalimab vs tacrolimus for new kidney transplant patients
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled to receive your first kidney transplant from a living or deceased donor.
- Your doctor considers you to be at low to moderate immunological risk.
- You have not had a previous organ transplant, including a previous kidney transplant.
- You do not have active infections like HIV, hepatitis B or C, or tuberculosis.
- You do not have certain conditions like a blood clotting disorder or a history of blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
This trial tests whether fingolimod can reduce kidney scarring and preserve kidney function after a new kidney transplant. It focuses on people who are in the early period after transplant who may be at risk for scarring in the kidney.
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
This trial tests a new drug, siplizumab, to see if it helps the body accept a donated kidney better than a standard treatment. It is for people receiving a kidney transplant from a living or deceased donor.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.